- |||||||||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Targeting the c-MET/HGF signaling pathway in pancreatic ductal adenocarcinoma. (Pubmed Central) - Nov 23, 2019
It is likely that within the next few years, HGF/Met inhibitors will become a crucial component for cancer management. In this review, we summarize the role of HGF/Met pathway in the pathogenesis of pancreatic cancer, with particular emphasize on HGF/Met inhibitors in the clinical setting, including Cabozantinib (XL184, BMS-907351), Crizotinib (PF-02341066), MK-2461, Merestinib (LY2801653), Tivantinib (ARQ197), SU11274, Onartuzumab (MetMab), Emibetuzumab (LY2875358), Ficlatuzumab (AV-299), Rilotumumab (AMG 102), NK4 in pancreatic cancer.
- |||||||||| MK-2461 / Merck (MSD)
Enrollment change, Metastases: MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED) (clinicaltrials.gov) - Apr 25, 2013
P1, N=25, Completed,
In this review, we summarize the role of HGF/Met pathway in the pathogenesis of pancreatic cancer, with particular emphasize on HGF/Met inhibitors in the clinical setting, including Cabozantinib (XL184, BMS-907351), Crizotinib (PF-02341066), MK-2461, Merestinib (LY2801653), Tivantinib (ARQ197), SU11274, Onartuzumab (MetMab), Emibetuzumab (LY2875358), Ficlatuzumab (AV-299), Rilotumumab (AMG 102), NK4 in pancreatic cancer. N=63 --> 25
|
